MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why HIND Stock advanced +1.74% Today — RQD Quant Desk Flash
$1.75 +1.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.75
Vyome Holdings Inc. (HIND) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $12.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.75 (+0.12%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HIND)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY HIND SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 21.9% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (23% of score)
20D Institutional Volume Accumulation (±11.7% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.09-10.5% Next Q
43
Q2 (-2Q)Grade D$1.87-4.3% Next Q
40
Q3 (-1Q)Grade E$1.79-2.2% Next Q
38
CurrentGrade D-$1.75-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HIND Turnaround Squeeze
While HIND currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.00) and Max Pain ($1.84) forces dealer call-delta covering toward $6.89.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HIND• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HIND Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HIND Stock advanced +1.74% Today — RQD Quant Desk Flash
Vyome Holdings Inc. (HIND) advanced +1.74% to $1.75, trading at 3% of its 52-week range ($1.62 – $6.56). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($1.62 – $6.56) with RSI-14 at 40.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.7% around $1.75 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 21.9% gross margin and $0 annual free cash flow.
Live HIND Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HIND)
- ✓Walkthrough of HIND's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HIND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.79%▼ DESCENDING CHANNEL
2026-10-30O $1.73H $2.14L $1.72C $1.75VOL 42.2K
RES: $2.23SUP: $1.61SMA50: $2.00SMA200: $2.24
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HIND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HIND today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HIND. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HIND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HIND)
Health Care Rank #828 of 1016
⚔️ BOLT vs HIND Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HIND vs. BOLT, KTTA, LPCN, BIVI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vyome Holdings Inc. (HIND) ranks #828 by composite RQD confidence (35/100, grade D-) and #876 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, HIND leads on earnings valuation at N/A trailing P/E, while HIND leads on capital efficiency and profitability with -35.0% ROIC and 68.4% gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with HIND at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HIND
ACTIVE
Vyome Holdings Inc. | D- | 35/100 | — | 68.4% | -35.0% | +1.74% | $12.3M | Benchmark Subject |
| BOLT Bolt Biotherapeutics Inc. | E | 28/100 | — | — | -35.0% | -3.34% | $12.3M | /bolt-vs-hind → |
| KTTA Pasithea Therapeutics Corp. | D | 44/100 | — | — | -35.0% | -5.95% | $12.3M | /ktta-vs-hind → |
| LPCN Lipocine Inc. | D- | 37/100 | — | — | -35.0% | +0.66% | $12.5M | /lpcn-vs-hind → |
| BIVI BioVie Inc. (Class A) | E | 33/100 | — | — | -35.0% | -5.48% | $12.0M | /bivi-vs-hind → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001427570In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vyome Holdings Inc. (HIND) reported GAAP revenue of $319.7K (-96.0% vs. FY2024 revenue of $8.0M , and -96.3% cumulative change since FY2023) , GAAP net income of -$10.3M, operating cash flow of -$3.7M, and free cash flow of -$3.7M (-510.4% YoY). On the balance sheet, HIND closed FY2025 with $6.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $319.7K | -$10.3M | -$3.7M | -$3.7M | $6.5M | — |
| FY2024 (FY) | 2024-12-31 | $8.0M | -$1.4M | -$614.1K | -$614.1K | $1.4M | — |
| FY2023 (FY) | 2023-12-31 | $8.7M | -$11.4M | -$17.0M | -$17.0M | — | — |
3. HIND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HIND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Vyome Holdings Inc. (NASDAQ: HIND) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.75 (+1.74% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HIND ranks #828 in composite RQD confidence.
How does HIND compare to BOLT and KTTA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HIND carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 68.4%, and ROIC of -35.0%. By comparison, BOLT (Bolt Biotherapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and KTTA (Pasithea Therapeutics Corp.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, HIND leads on earnings multiple (N/A) while HIND leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HIND?
Per HIND's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001427570), Vyome Holdings Inc. generated $319.7K in revenue (-96.0% YoY), -$10.3M in net income, and -$3.7M in free cash flow against $6.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HIND trading relative to its 50-day, 200-day, and 52-week technical levels?
HIND last traded at $1.75 (+1.74% on volume of 13,164 shares), positioning the stock -12.50% below its 50-day simple moving average ($2.00) and -21.88% below its 200-day simple moving average ($2.24). Across its 52-week range of $1.62 to $6.56, HIND sits at the 2.6% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($1.55 to $1.95).
HIND Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HIND stock moving today?
Why HIND Stock advanced +1.74% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.